Ipca Laboratories Limited reported a strong financial performance for the third quarter of FY25, with a notable rise in both revenue and net profit.
The company’s revenue from operations stood at ₹2,245.37 crore, marking a 9.4% year-on-year (YoY) growth from ₹2,052.85 crore in Q3 FY24. The total income for the quarter was ₹2,265.48 crore, up from ₹2,075.30 crore in the same period last year.
At the profitability level, net profit attributable to owners of the company surged 38% YoY to ₹248.14 crore, compared to ₹179.88 crore in the year-ago quarter. The strong profit growth was supported by improved operational performance and cost efficiencies.
Key Highlights:
- EBITDA: ₹367.92 crore, up significantly from ₹220.43 crore in Q3 FY24.
- Tax Expenses: ₹90.59 crore compared to ₹66.53 crore last year.
- Total Expenses: Increased to ₹1,897.56 crore, reflecting higher material and employee costs.
For the nine-month period ending December 31, 2024, Ipca reported a total revenue of ₹6,759.88 crore, registering a YoY growth of 17%. The net profit for the same period stood at ₹669.86 crore, up from ₹487.76 crore in the previous year.
The company continues to maintain its strong position in the pharmaceutical sector with steady revenue growth and improved margins.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
